Please wait while the formulary information is being retrieved.
ZEJULA (NIRAPARIB TOSYLATE)
- Malignant epithelial tumor of ovary
- Malignant neoplasm of fallopian tube
- Primary malignant neoplasm of peritoneum
100 mg capsule
- 3 capsules (300 mg) by oral route once daily at approximately the same time each day
Malignant epithelial tumor of ovary
- 1 capsule (100 mg) by oral route once daily at approximately thesame time each day
- 2 capsules (200 mg) by oral route once daily at approximately the same time each day
- 3 capsules (300 mg) by oral route once daily at approximately the same time each day
Malignant neoplasm of fallopian tube
- 1 capsule (100 mg) by oral route once daily at approximately thesame time each day
- 2 capsules (200 mg) by oral route once daily at approximately the same time each day
- 3 capsules (300 mg) by oral route once daily at approximately the same time each day
Primary malignant neoplasm of peritoneum
- 1 capsule (100 mg) by oral route once daily at approximately thesame time each day
- 2 capsules (200 mg) by oral route once daily at approximately the same time each day
- 3 capsules (300 mg) by oral route once daily at approximately the same time each day
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Myelodysplastic syndrome
- Neutropenic disorder
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Cardiac arrhythmia
- Hypertension
ZEJULA (NIRAPARIB TOSYLATE)
- Malignant epithelial tumor of ovary
- Malignant neoplasm of fallopian tube
- Primary malignant neoplasm of peritoneum
- Abnormal hepatic function tests
- Anemia
- Hypertension
- Leukopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Abdominal distension
- Acute abdominal pain
- Anorexia
- Arthralgias
- Back pain
- Constipation
- Cough
- Diarrhea
- Dizziness
- Dysgeusia
- Dyspepsia
- Dyspnea
- Fatigue
- General weakness
- Headache disorder
- Insomnia
- Myalgias
- Nausea
- Palpitations
- Pharyngitis
- Skin rash
- Stomatitis
- Symptoms of anxiety
- Urinary tract infection
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- Hypokalemia
- Bronchitis
- Conjunctivitis
- Depression
- Epistaxis
- Peripheral edema
- Tachycardia
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myeloid leukemia
- Anaphylaxis
- Hypersensitivity drug reaction
- Hypertensive crisis
- Interstitial pneumonitis
- Myelodysplastic syndrome
- Posterior reversible encephalopathy syndrome
Less Severe
- Acute confusion
- Hallucinations
- Skin photosensitivity
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Niraparib
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Niraparib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Niraparib
Manufacturer does not rec during and for 1 mo after treatment
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Manufacturer does not rec during and for 1 mo after treatment |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Malignant epithelial tumor of ovary | |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| Malignant neoplasm of fallopian tube | |
| C57.0 | Malignant neoplasm of fallopian tube |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| Primary malignant neoplasm of peritoneum | |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| 0-9 | A-Z |
|---|---|
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.0 | Malignant neoplasm of fallopian tube |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
Formulary Reference Tool